Search Results - "Marco, Jose García"

Long‐term follow‐up of dose‐adjusted EPOCH plus rituximab (DA‐EPOCH‐R) in untreated patients with poor prognosis large B‐cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group by Purroy, Noelia, Bergua, Juan, Gallur, Laura, Prieto, Julio, Lopez, Luis A., Sancho, Juan M., García‐Marco, Jose A., Castellví, Josep, Montes‐Moreno, Santiago, Batlle, Ana, Villambrosia, Sonia Gonzalez, Carnicero, Fernando, Ferrando‐Lamana, Lucía, Piris, Miguel A, Lopez, Andrés

“…Summary This prospective multi‐institutional phase II study was designed to assess the efficacy and safety of dose‐adjusted EPOCH (etoposide,…”
Get full text

Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells by Sánchez-Martínez, Diego, Lanuza, Pilar M, Gómez, Natalia, Muntasell, Aura, Cisneros, Elisa, Moraru, Manuela, Azaceta, Gemma, Anel, Alberto, Martínez-Lostao, Luis, Villalba, Martin, Palomera, Luis, Vilches, Carlos, García Marco, José A, Pardo, Julián

“…Mutational status of together with expression of wild-type (wt) represents the most widely accepted biomarkers, establishing a very poor prognosis in B-cell…”
Get full text

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia by Abrisqueta, Pau, Villamor, Neus, Terol, María José, González-Barca, Eva, González, Marcos, Ferrà, Christelle, Abella, Eugenia, Delgado, Julio, García-Marco, Jose A., González, Yolanda, Carbonell, Felix, Ferrer, Secundino, Monzó, Encarna, Jarque, Isidro, Muntañola, Ana, Constants, Mireia, Escoda, Lourdes, Calvo, Xavier, Bobillo, Sabela, Montoro, José Bruno, Montserrat, Emili, Bosch, Francesc

“…The effectiveness of rituximab maintenance therapy in the treatment of chronic lymphocytic leukemia has been investigated in a phase 2 clinical trial that…”
Get full text

Allogeneic Transplant with Reduced Intensity Conditioning Regimens may Overcome the Poor Prognosis of B-Cell Chronic Lymphocytic Leukemia with Unmutated Immunoglobulin Variable Heavy-Chain Gene and Chromosomal Abnormalities (11q− and 17p−) by CABALLERO, Dolores, GARCIA-MARCO, Jose A, GONZALEZ, Marcos, SIERRA, Jorge, SAN MIGUEL, Jesus, MARTINO, Rodrigo, MATEOS, Victoria, RIBERA, José M, SARRA, José, LEON, Angel, SANZ, Guillermo, DE LA SERNA, Javier, CABRERA, Rafael

“…Purpose: To evaluate the efficacy of reduced intensity conditioning (RIC) allogeneic transplant in 30 patients with poor-prognosis chronic lymphocytic leukemia…”
Get full text

Severe hemorrhage because of delayed iliac vein rupture after dialysis catheter placement: Is it preventable? by Sirvent, Ana E., Enríquez, Ricardo, Millán, Isabel, García‐Marco, Jose M., Rodríguez‐Czaplicki, Elías, Redondo‐Pachón, Maria D., González, César, Amorós, Francisco

“…Mechanical complications of femoral catheterization for hemodialysis include pseudoaneurysm, arteriovenous fistulae, neurological injury, and vessel…”
Get full text

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial by Byrd, John C, Hillmen, Peter, Ghia, Paolo, Kater, Arnon P, Chanan-Khan, Asher, Furman, Richard R, O'Brien, Susan, Yenerel, Mustafa Nuri, Illés, Arpad, Kay, Neil, Garcia-Marco, Jose A, Mato, Anthony, Pinilla-Ibarz, Javier, Seymour, John F, Lepretre, Stephane, Stilgenbauer, Stephan, Robak, Tadeusz, Rothbaum, Wayne, Izumi, Raquel, Hamdy, Ahmed, Patel, Priti, Higgins, Kara, Sohoni, Sophia, Jurczak, Wojciech

“…Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy…”
Get full text

PLCG1 mutations in cutaneous T-cell lymphomas by Vaqué, José P., Gómez-López, Gonzalo, Monsálvez, Verónica, Varela, Ignacio, Martínez, Nerea, Pérez, Cristina, Domínguez, Orlando, Graña, Osvaldo, Rodríguez-Peralto, José L., Rodríguez-Pinilla, Socorro M., González-Vela, Carmen, Rubio-Camarillo, Miriam, Martín-Sánchez, Esperanza, Pisano, David G., Papadavid, Evangelia, Papadaki, Theodora, Requena, Luis, García-Marco, José A., Méndez, Miriam, Provencio, Mariano, Hospital, Mercedes, Suárez-Massa, Dolores, Postigo, Concepción, San Segundo, David, López-Hoyos, Marcos, Ortiz-Romero, Pablo L., Piris, Miguel A., Sánchez-Beato, Margarita

“…Cutaneous T-cell lymphoma (CTCL) is a heterogeneous group of primary cutaneous T-cell lymphoproliferative processes, mainly composed of mycosis fungoides and…”
Get full text

Matrix Metalloproteinase-9 Promotes Chronic Lymphocytic Leukemia B Cell Survival through Its Hemopexin Domain by Redondo-Muñoz, Javier, Ugarte-Berzal, Estefanía, Terol, María José, Van den Steen, Philippe E., Hernández del Cerro, Mercedes, Roderfeld, Martin, Roeb, Elke, Opdenakker, Ghislain, García-Marco, José A., García-Pardo, Angeles

“…Matrix metalloproteinase-9 (MMP-9) is the major MMP produced by B-CLL cells and contributes to their tissue infiltration by degrading extracellular and…”
Get full text

Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry by QUIJANO, Sandra, LOPEZ, Antonio, PENALVER, Francisco Javier, PLAZA-VILLA, Josefa, MORADO, Marta, GARCIA-MARCO, José, ARIAS, Jesus, BRIONES, Javier, FERRER, Secundino, CAPOTE, Javier, NICOLAS, Concepcion, ORFAO, Alberto, SANCHO, Juan Manuel, PANIZO, Carlos, DEBEN, Guillermo, CASTILLA, Cristina, GARCIA-VELA, José Antonio, SALAR, Antonio, ALONSO-VENCE, Natalia, GONZALEZ-BARCA, Eva

“…Here, we evaluate the sensitivity and specificity of a new 11-parameter flow cytometry (FCM) approach versus conventional cytology (CC) for detecting…”
Get full text

Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM) by González-Rincón, Julia, Garcia-Vela, José A, Gómez, Sagrario, Fernández-Cuevas, Belén, Nova-Gurumeta, Sara, Pérez-Sanz, Nuria, Alcoceba, Miguel, González, Marcos, Anguita, Eduardo, López-Jiménez, Javier, González-Barca, Eva, Yáñez, Lucrecia, Pérez-Persona, Ernesto, de la Serna, Javier, Fernández-Zarzoso, Miguel, Deben, Guillermo, Peñalver, Francisco J, Fernández, María C, de Oteyza, Jaime Pérez, Andreu, M Ángeles, Ruíz-Guinaldo, M Ángeles, Paz-Arias, Raquel, García-Malo, M Dolores, Recasens, Valle, Collado, Rosa, Córdoba, Raúl, Navarro-Matilla, Belén, Sánchez-Beato, Margarita, García-Marco, José A

“…Chronic Lymphocytic Leukemia (CLL) is the most prevalent leukemia in Western countries and is notable for its variable clinical course. This variability is…”
Get full text

MMP-9 affects gene expression in chronic lymphocytic leukemia revealing CD99 as an MMP-9 target and a novel partner in malignant cell migration/arrest by Aguilera-Montilla, Noemí, Bailón, Elvira, Uceda-Castro, Rebeca, Ugarte-Berzal, Estefanía, Santos, Andrea, Gutiérrez-González, Alejandra, Pérez-Sánchez, Cristina, Van den Steen, Philippe E., Opdenakker, Ghislain, García-Marco, José A., García-Pardo, Angeles

“…We previously showed that MMP-9 contributes to CLL pathology by regulating cell survival and migration and that, when present at high levels, MMP-9 induces…”
Get full text

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia by BOSCH, Francesc, ABRISQUETA, Pau, GARCIA MARCO, José Antonio, ESCODA, Lourdes, FERRER, Secundino, MONZO, Encarnación, GONZALEZ, Yolanda, ESTANY, Cristina, JARQUE, Isidro, SALAMERO, Olga, MUNTANOLA, Ana, MONTSERRAT, Emili, VILLAMOR, Neus, TEROL, Maria José, GONZALEZ-BARCA, Eva, FERRA, Christelle, GONZALEZ DIAZ, Marcos, ABELLA, Eugenia, DELGADO, Julio, CARBONELL, Félix

“…The addition of monoclonal antibodies to chemotherapy has significantly improved treatment of chronic lymphocytic leukemia (CLL). Based on excellent results…”
Get full text

Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia by Robak, Tadeusz, Hellmann, Andrzej, Kloczko, Janusz, Loscertales, Javier, Lech‐Maranda, Ewa, Pagel, John M., Mato, Anthony, Byrd, John C., Awan, Farrukh T., Hebart, Holger, Garcia‐Marco, Jose A., Hill, Brian T., Hallek, Michael, Eisenfeld, Amy J., Stromatt, Scott C., Jaeger, Ulrich

“…Summary Otlertuzumab (TRU‐016) is a humanized anti‐CD37 protein therapeutic that triggers direct caspase‐independent apoptosis of malignant B cells and induces…”
Get full text

Matrix metalloproteinase-9 induces a pro-angiogenic profile in chronic lymphocytic leukemia cells by Aguilera-Montilla, Noemí, Bailón, Elvira, Ugarte-Berzal, Estefanía, Uceda-Castro, Rebeca, Prieto-Solano, María, García-Martínez, Elena, Samaniego, Rafael, Van den Steen, Philippe E., Opdenakker, Ghislain, García-Marco, José A., García-Pardo, Angeles

“…Increased angiogenesis is commonly observed in chronic lymphocytic leukemia (CLL) tissues in correlation with advanced disease. CLL cells express pro- and…”
Get full text

Matrix metalloproteinase-9 is involved in chronic lymphocytic leukemia cell response to fludarabine and arsenic trioxide by Amigo-Jiménez, Irene, Bailón, Elvira, Ugarte-Berzal, Estefanía, Aguilera-Montilla, Noemí, García-Marco, José A, García-Pardo, Angeles

“…Matrix metalloproteinase-9 (MMP-9) contributes to chronic lymphocytic leukemia (CLL) pathology by regulating cell migration and preventing spontaneous…”
Get full text

New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing by Doménech, Elena, Gómez-López, Gonzalo, Gzlez-Peña, Daniel, López, Mar, Herreros, Beatriz, Menezes, Juliane, Gómez-Lozano, Natalia, Carro, Angel, Graña, Osvaldo, Pisano, David G, Domínguez, Orlando, García-Marco, José A, Piris, Miguel A, Sánchez-Beato, Margarita

“…Chronic lymphocytic leukemia (CLL) is a heterogeneous disease without a well-defined genetic alteration responsible for the onset of the disease. Several lines…”
Get full text

HLA‐partially matched cellular therapy (stem‐cell microtransplantation) for acute myeloid leukaemia: description of four cases by Forés, Rafael, Dorado, Nieves, Vilches, Carlos, Regidor, Carmen, García‐Marco, José A., Pablo, Rosario, Laiglesia, Almudena, Lario, Ana, Piris, Miguel, Cabrera, J. Rafael

Get full text

A Novel CD44-binding Peptide from the Pro-Matrix Metalloproteinase-9 Hemopexin Domain Impairs Adhesion and Migration of Chronic Lymphocytic Leukemia (CLL) Cells by Ugarte-Berzal, Estefanía, Bailón, Elvira, Amigo-Jiménez, Irene, Albar, Juan Pablo, García-Marco, José A., García-Pardo, Angeles

“…(pro)MMP-9 binds to CLL cells through the PEX9 domain and contributes to CLL progression. To biochemically characterize this interaction and identify potential…”
Get full text

Arsenic trioxide synergistically potentiates the cytotoxic effect of fludarabine in chronic lymphocytic leukemia cells by further inactivating the Akt and ERK signaling pathways by Lozano-Santos, Carol, Amigo-Jiménez, Irene, Nova-Gurumeta, Sara, Pérez-Sanz, Nuria, García-Pardo, Angeles, García-Marco, José A.

“…CLL remains an incurable disease, making it crucial to continue searching for new therapies efficient in all CLL cases. We have studied the effect of combining…”
Get full text

Overexpression of progelatinase B/proMMP‐9 affects migration regulatory pathways and impairs chronic lymphocytic leukemia cell homing to bone marrow and spleen by Bailón, Elvira, Ugarte‐Berzal, Estefanía, Amigo‐Jiménez, Irene, Van den Steen, Philippe, Opdenakker, Ghislain, García‐Marco, José A., García‐Pardo, Angeles

“…Elevated (pro)MMP‐9 expression alters key regulatory molecules (ERK, FAK, RhoAGTPase, PTEN) and impairs CLL cell migration, favoring organ retention and…”
Get full text